ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026
[A Study on the Relationship Between Cyclic Inflammatory Protein Fibroblast Growth Factor 21, Osteoporosis, and Fractures].
Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Systematically conduct a screening of the potential targets within circulating inflammatory proteins (CIPs) that have an impact on osteoporosis (OP) and fractures. Validate their association with bone mineral density (BMD) via clinical samples, thereby offering novel evidence for the regulation of bone metabolism. Methods: The study employs bidirectional Mendelian randomization analysis to investigate the causal relationship between CIPs and OP, as well as fractures. Two groups are included: patients with type 2 diabetes mellitus (T2DM) and healthy individuals. General patient data are collected, and fibroblast growth factor 21 (FGF21) and bone metabolism indicators are measured and compared among the T2DM group with OP (DOP), the T2DM group without OP (NDOP), and the control group. Results: Among the 91 types of CIPs retrieved from the EBI GWAS Catalog database, the inverse variance weighting (IVW) analysis indicated that FGF21 potentially had a causal relationship with both OP and fractures that transpired within the past five years. An elevation in its level augmented the risk of OP (odds ratio [OR] = 1.003, 95% CI: 1.001-1.005; Conclusion: FGF21 elevates the risk of OP and fractures that have occurred over the past five years, and a causal relationship exists. It serves as a potential risk factor for impaired bone health in T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.